
Commentary|Videos|March 13, 2025
Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC
Author(s)Daniel J. George, MD, Matthew Smith, MD, PhD
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Advertisement
Episodes in this series

Advertisement
Related to this article

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
4
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
5
